ArticleCNS neuroscience & therapeutics2019
Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta-analysis.
Article in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Pooled it
- Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis.Frontiers in neurology · 2024Pooled it
- Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Immunomodulators and immunosuppressants for myasthenia gravis: a network meta-analysis.The Cochrane database of systematic reviews · 2025Article
- Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study.Frontiers in neurology · 2023Article
- Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients.World journal of psychiatry · 2022Article
- Effects of Natural Products on Neuromuscular Junction.Current neuropharmacology · 2022Review
- Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.Journal of translational medicine · 2021Article
- Immunotherapy choice and maintenance for generalized myasthenia gravis in China.CNS neuroscience & therapeutics · 2020Article
- Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta-analysis.CNS neuroscience & therapeutics · 2019Article
- Autoimmune Channelopathies at Neuromuscular Junction.Frontiers in neurology · 2019Review
- Eculizumab in myasthenia gravis: A review.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe intended to compare and rank all the immunotherapies including immunosuppressant agents or monoclonal antibodies for myasthenia gravis (MG).
methodsA network meta-analysis was performed to synthesize the direct evidence and indirect evidence. Quantitative MG score (QMGS) was defined as the primary outcome. The secondary outcomes included the glucocorticoid reduction and hazard ratios (HR) from the counts of adverse events (AEs).
resultsWe identified 14 studies including 808 MG patients. For the primary outcome, cyclosporine A (CsA) was hierarchically the best with statistical significances of -1.18 (-1.81, -0.59) vs placebo (PLA), -0.98 (-1.72, -0.23) vs mycophenolate mofetil, and -0.77 (-1.57, -0.032) vs tacrolimus (TAC). When the intervention periods were controlled, both eculizumab (ECZ) of -1.50 (-2.81, -0.18) and CsA of -1.23 (-1.81, -0.64) vs PLA reached a statistical significance. Belimumab and ECZ ranked the most tolerable therapies while CsA of 2.41 (0.58, 10.01) ranked the last vs PLA.
conclusionThese findings demonstrated that ECZ represented the most effective and tolerable therapeutic alternative to be recommended for refractory MG. TAC may be a beneficial therapy to treat MG extensively while the efficacy of CsA and cyclophosphamide may be limited by their multiple or severe AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.